Order Article Reprints

Gerner B, Aghai-Trommeschlaeger F, Kraus S, Grigoleit GU, Zimmermann S, Kurlbaum M, Klinker H, Isberner N, Scherf-Clavel O. A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug–Drug Interaction Frequently Observed in Graft versus Host Disease Patients. Pharmaceutics. 2022; 14(12):2556. https://doi.org/10.3390/pharmaceutics14122556

Gerner, Bettina, Fatemeh Aghai-Trommeschlaeger, Sabrina Kraus, Götz Ulrich Grigoleit, Sebastian Zimmermann, Max Kurlbaum, Hartwig Klinker, Nora Isberner, and Oliver Scherf-Clavel. 2022. "A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug–Drug Interaction Frequently Observed in Graft versus Host Disease Patients" Pharmaceutics 14, no. 12: 2556. https://doi.org/10.3390/pharmaceutics14122556

Gerner, B., Aghai-Trommeschlaeger, F., Kraus, S., Grigoleit, G. U., Zimmermann, S., Kurlbaum, M., Klinker, H., Isberner, N., & Scherf-Clavel, O. (2022). A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug–Drug Interaction Frequently Observed in Graft versus Host Disease Patients. Pharmaceutics, 14(12), 2556. https://doi.org/10.3390/pharmaceutics14122556